Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BBOT stock hub

BridgeBio Oncology Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BBOTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

613.1M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BBOT

In the news

Latest news · BBOT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-48.2

P25 -106.6P50 -46.9P75 -3.1

ROIC-32.6

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BBOT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

168

Groups with data

Currency

USD

Showing 168 of 168 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001869105
Company name	BridgeBio Oncology Therapeutics, Inc.
Country	United States
Country code	US
Employees	92
Enterprise value	$190.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US1079241022
Last refreshed	2026-05-10
Market cap	$613.1M
Market cap category	Small-Cap
Price	$7.66
Price currency	USD
Sector	Healthcare
Symbol	BBOT
Website	https://bbotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-21.87%
FCF yield	-18.68%
P/B ratio	1.49x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-134M
Net Income Growth Years	0%
Profit Per Employee	$-1.5M
ROA	-29.75
ROCE	-35.28
ROE	-48.23
ROIC	-32.63

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-29.42%
EPS Growth Quarters	3
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$448.4M
Cash	$425.5M
Current Assets	$432.4M
Current Liabilities	$35M
Debt	$2.8M
Debt Equity	$0.01
Equity	$411.1M
Liabilities	$37.3M
Long Term Assets	$16M
Long Term Liabilities	$2.2M
Net Cash	$422.7M
Net Cash By Market Cap	$68.95
Net Cash Growth	171.6%
Net Debt Equity	$-1.03
Tangible Book Value	$411.1M
Tangible Book Value Per Share	$5.14
WACC	5.44

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.34
Net Working Capital	$-27.6M
Quick ratio	12.15
Working Capital	$397.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-241,276.23%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-29.4%
200-day SMA	10.81
50-day SMA	9.05
50-day SMA vs 200-day SMA	50under200
All Time High	14.87
All Time High Change	-48.49%
All Time High Date	2025-12-08
All Time Low	7.6
All Time Low Change	0.79%
All Time Low Date	2026-05-07
ATR	0.56
Beta	0.22
Beta1y	0.49
Beta2y	0.16
Ch YTD	-38.82
High	7.99
High52	14.87
High52 Date	2025-12-08
High52ch	-48.49%
Low	7.64
Low52	7.6
Low52 Date	2026-05-07
Low52ch	0.79%
Ma50ch	-15.33%
Premarket Change Percent	-2.04
Premarket Price	$7.7
Premarket Volume	10,707
Price vs 200-day SMA	-29.14%
RSI	33.2
RSI Monthly	31.14
RSI Weekly	34.92
Sharpe ratio	-0.31x
Sortino ratio	-0.37
Total Return	-241,276.23%
Tr YTD	-38.82
Tr1m	-8.81%
Tr1w	-8.7%
Tr3m	-28.41%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	3
Analyst Price Target Top	$22.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.51
Operating Income	$-145.8M
Price target	$24
Price Target Change	$213
Price Target Change Top	$196

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	35,678,144%
Float Percent	44.58%
Shares Insiders	0.01%
Shares Institutions	41.34%
Shares Out	80,032,823
Shares Qo Q	83.92%
Shares Yo Y	241,276.23%
Short Float	9.07%
Short Ratio	11.78
Short Shares	4.04

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-120.4M
Average Volume	481,082.35x
Bv Per Share	5.14
CAPEX	$-606,000
Ch1m	-8.81
Ch1w	-8.7
Ch1y	-29.4
Ch3m	-28.41
Ch6m	-36.95
Change	-2.54%
Change From Open	-2.54
Close	7.86
Days Gap	0
Depreciation Amortization	280,000
Dollar Volume	1,823,876.6
Earnings Date	2026-05-26
Earnings Time	bmo
EBIT	$-145.8M
EBITDA	$-145.5M
EPS	$-4.3
F Score	2
FCF	$-114.5M
FCF EV Yield	-60.15x
FCF Per Share	$-1.43
Financing CF	383,402,000
Fiscal Year End	December
Founded	2,016
Investing CF	73,328,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-05
Last Report Date	2025-12-31
Last Split Type	Never
Ma150	10.94
Ma150ch	-30.01%
Ma20	8.72
Ma20ch	-12.19%
Net CF	342,836,000
Next Earnings Date	2026-05-26
Open	7.86
Optionable	No
Position In Range	5.71
Post Close	7.66
Postmarket Change Percent	-0.78
Postmarket Price	$7.6
Ppne	3,286,000
Pre Close	7.86
Price Date	2026-05-08
Ptbv Ratio	1.49
Relative Volume	0.49x
Share Based Comp	5,873,000
Tr6m	-36.95%
Us State	California
Volume	238,104

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BBOT pay a dividend?

Capital-return profile for this ticker.

Performance

BBOT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BBOT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+41.3%

Float: +44.6% of shares outstanding

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BBOT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

33.2

Neutral momentum band

Price vs 200-day MA

-29.1%

50/200-day relationship not available

Beta (5Y)

0.22

Less volatile than the market

Sharpe ratio

-0.31

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BBOT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BBOT stock rating?

BridgeBio Oncology Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BBOT analysis?

The full report lives at /stocks/BBOT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BBOT?

The latest report frames BBOT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BBOT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.